Skip to content
MarketScale
‹ Back to IndustriesHealthcare

PRES-FLEX MINIMIZES WASTE TO MAINTAIN REGULATORY STANDARDS

Pres-Flex is an industry leader in film innovation. For more than 50 years, we have produced and supplied customized film designed specifically for the vinyl floor industry. Presco recently reformulated their vinyl flooring film with a plasticizer that is REACH registered as a non-ortho-phthalate plasticizer. Through the modification of traditional formulas, our expert engineers were able to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Pres-Flex is an industry leader in film innovation. For more than 50 years, we have produced and supplied customized film designed specifically for the vinyl floor industry. Presco recently reformulated their vinyl flooring film with a plasticizer that is REACH registered as a non-ortho-phthalate plasticizer. Through the modification of traditional formulas, our expert engineers were able to remove heavy metals and phthalates to stay in line with demand, industry regulations, and health standards.

Modifications for Regulatory Standards

Petroleum-based elements typically used in vinyl manufacture are reduced with formulations utilizing bio-based raw materials like plasticizers. Ethylene Vinyl Acetate (EVA) film extrusion (EVA), a member of the polyolefin family, is an exciting addition to the Pres-Flex product line, marking the first PVC-free manufacturing capability for Pres-Flex Engineered Film. Minus the plasticizers found in PVC, EVA meets both regulatory and health standards, as well as client demand. This is especially significant for medical practices that require PVC-free film.

Green Manufacturing the Presco Way

Presco prides itself on its green culture, and real time recycling in production helps eliminate waste while maximizing customer dollars. Presco not only consumes all the waste we generate, but purchases post-industrial vinyl film waste from other manufacturers, then converts it to regrind. When formulations permit, the regrind is mixed into production orders. This allows for internal consumption of scrap while lowering overall pricing for our customers. In addition, Pres-Flex Floor Covering Films are 100% recyclable

Unique Customization

Our unique dry-blend compounding process allows for customization during every level of the formulation process. Speciality resins such as molecular weight resins, and many plasticizers are utilized. And based on specifications, we can provide heavy metal-free, DEHP-free, and phthalate-free formulations, with specialty additives like flame retardants, antimicrobials, dulling agents, aromatics, and UV stabilizers. Further, our films are not only available with custom pigmentation, dimensional fillers, and other features, but range from flexible to semi-rigid, allowing for easy integration into vinyl tile manufacturing processes. Additionally, thicknesses can range from 2mil to 2mil, and widths up to 94”. (All formulations are subject to minimums and lead times.)

At Pres-Flex, we took a fresh look at long-standing industry methods and reworked raw material formulations to meet regulatory and health changes without sacrificing product quality or performance. For more information regarding our EVA engineered film, extrusion coated films, and our numerous other capabilities, please visit www.pres-flex.com. And to learn more about Presco’s rich history with roots dating back to 1942, please click here.

Read more at pres-flex.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512